Co-Diagnostics
CODX
45 hedge funds and large institutions have $6.27M invested in Co-Diagnostics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 2 closing their positions.
547% more call options, than puts
Call options by funds: $330K | Put options by funds: $51K
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
30% more capital invested
Capital invested by funds: $4.83M → $6.27M (+$1.44M)
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
5% more funds holding
Funds holding: 43 → 45 (+2)
0.03% more ownership
Funds ownership: 0.49% → 0.51% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$88K |
| 2 |
Man Group
London,
United Kingdom
|
+$87.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$31K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$28.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$28.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KOC
Koss-Olinger Consulting
Gainesville,
Florida
|
-$62.4K |
| 2 |
Renaissance Technologies
New York
|
-$22.8K |
| 3 |
AC
Aristides Capital
Louisville,
Kentucky
|
-$15.9K |
| 4 |
PWG
Portside Wealth Group
Provo,
Utah
|
-$13K |
| 5 |
PWA
Physician Wealth Advisors
Midvale,
Utah
|
-$9.41K |
CODX Hedge Fund Activity: Q4 2023 in Review
45 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q4 2023, worth a combined $6.27M — up 30% from $4.83M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CODX positions and 2 closed out — a net gain of 3 holders — while 13 added to existing stakes and 11 trimmed.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $88K. The largest seller was Koss-Olinger Consulting, cutting an estimated $62.4K.
- 45 institutional investors held Co-Diagnostics (CODX) as of Q4 2023, up from 43 in Q3 2023.
- Funds reported $6.27M of Co-Diagnostics stock for Q4 2023, up 30% quarter-over-quarter.
- 5 funds opened new Co-Diagnostics positions in Q4 2023 and 2 closed out, a net change of +3 holders.
- The largest Co-Diagnostics buyer in Q4 2023 was Bank of Montreal, an estimated $88K added.
- The largest Co-Diagnostics seller in Q4 2023 was Koss-Olinger Consulting, an estimated $62.4K sold.
Based on aggregated 13F filings for Q4 2023.